Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


pMSCVpuro-Flag-cMyc T58A Citations (7)

Originally described in: Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes.
Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilić J, Pekarik V, Tiscornia G, Edel M, Boué S, Belmonte JC Nat Biotechnol. 2008 Nov . 26(11):1276-84.
PubMed Journal

Articles Citing pMSCVpuro-Flag-cMyc T58A

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ. Nat Med. 2011 Aug 7;17(9):1116-20. doi: 10.1038/nm.2402. PubMed
Expression and function of nuclear receptor coactivator 4 isoforms in transformed endometriotic and malignant ovarian cells. Rockfield S, Flores I, Nanjundan M. Oncotarget. 2017 Dec 28;9(4):5344-5367. doi: 10.18632/oncotarget.23747. eCollection 2018 Jan 12. PubMed
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001. PubMed
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. Yi J, Liu C, Tao Z, Wang M, Jia Y, Sang X, Shen L, Xue Y, Jiang K, Luo F, Liu P, Cheng H. EBioMedicine. 2019 May;43:225-237. doi: 10.1016/j.ebiom.2019.03.027. Epub 2019 Mar 18. PubMed
Chronic iron exposure and c-Myc/H-ras-mediated transformation in fallopian tube cells alter the expression of EVI1, amplified at 3q26.2 in ovarian cancer. Rockfield S, Kee Y, Nanjundan M. Oncogenesis. 2019 Aug 21;8(9):46. doi: 10.1038/s41389-019-0154-y. PubMed
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3beta-Mediated c-Myc and Pim-1 Proteasomal Degradation. Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. Mol Cancer Ther. 2021 Apr;20(4):676-690. doi: 10.1158/1535-7163.MCT-20-0663. Epub 2021 Feb 10. PubMed
Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. Scarpa M, Kapoor S, Tvedte ES, Doshi KA, Zou YS, Singh P, Lee JK, Chatterjee A, Ali MKM, Bromley RE, Hotopp JCD, Rassool FV, Baer MR. Oncotarget. 2021 Aug 31;12(18):1763-1779. doi: 10.18632/oncotarget.28042. eCollection 2021 Aug 31. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.